Skip to main content

Table 6 Chemotherapy details

From: Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study

Cycles Cetuximab + CCRT
(n = 62)
CCRT
(n = 124)
Triweekly regimen
 1 1 (1.6%) 0 (0.0%)
 2 28 (45.2%) 50 (40.3%)
 3 10 (16.1%) 14 (11.3%)
Weekly regimen
 4 1 (1.6%) 4 (3.2%)
 5 4 (6.5%) 16 (12.9%)
 6 16 (25.8%) 31 (25%)
 7 2 (3.2%) 9 (7.3%)